Inoviem

Inoviem Scientific is a specialized contract research organization (CRO) offering a suite of label-free analytical services to biopharma clients. Its core value proposition is the use of its proprietary NPOT® and PIMS® technologies to study unmodified drug candidates in their native biological context, primarily using human tissue samples, to bridge the gap between pre-clinical models and clinical outcomes. This approach aims to de-risk pipelines, improve clinical trial design through biomarker discovery and patient stratification, and ultimately increase the likelihood of clinical success. The company serves partners developing small molecules and biologics across oncology, autoimmune, metabolic, and other disease areas.

Proprietary label-free platforms including NPOT® (for mechanism of action deconvolution in native tissues), PIMS® (for predictive interaction mapping and patient stratification), and LIPS (for label-free interaction profiling), supported by SPR and proteomics.

Inoviem competes in a fragmented market against large global CROs (e.g., Charles River, LabCorp) that offer broad service portfolios and scale, as well as specialized players focusing on complex in-vitro models (organoids, 3D cultures), AI-driven discovery, and other label-free interaction analysis technologies. Its differentiation lies in the specific combination of label-free analysis applied directly to native human tissues.